Skip to main content

Novo Holdings A/S

13F filer · CIK 0001388325
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.72BU.S. long equity reported on 13F
Positions256 new · 3 closed
Net flow last quarter+$205MBuys minus sells
Top 10 positions weight73.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202625 positions
EWTXEdgewise Therapeutics, Inc.$217M12.62%4.96%Not reportedQ1 2021
ASMLAsml Holding NV$189M10.97%0.02%Not reportedQ1 2022
COAGHemab Therapeutics Holdings, Inc.$154M8.92%8.95%NewQ2 2026
BNBROOKFIELD Corp$150M8.68%Not reportedNot reportedQ3 2023
MPLTMapLight Therapeutics, Inc.$132M7.67%8.11%Not reportedQ4 2025
MIRMMirum Pharmaceuticals, Inc.$132M7.65%1.74%-15.1%Q3 2019
AVLNAvalyn Pharma Inc.$128M7.42%8.76%NewQ2 2026
CRMSalesforce, Inc.$61.6M3.58%0.05%Not reportedQ1 2022
AVBPArriVent BioPharma, Inc.$52.1M3.03%3.10%-22.8%Q1 2024
ELVNEnliven Therapeutics, Inc.$50.8M2.95%1.37%-21.9%Q2 2025
CRNXCrinetics Pharmaceuticals, Inc.$49.4M2.87%1.25%-14.8%Q3 2018
PHVSPharvaris N.V.$48.4M2.81%2.15%-20.0%Q1 2021
FNDFloor & Decor Holdings, Inc.$47.3M2.75%0.75%NewQ2 2026
PCVXVaxcyte, Inc.$46.5M2.70%0.55%-7.0%Q2 2020
FDMT4D Molecular Therapeutics, Inc.$43.2M2.51%5.88%-11.0%Q1 2023
VRDNViridian Therapeutics, Inc.\DE$39.2M2.28%1.89%+6.8%Q1 2024
CLDXCelldex Therapeutics, Inc.$38.1M2.21%1.31%-14.6%Q2 2024
ALMSAlumis Inc.$31M1.80%Not reportedNewQ2 2026
XENEXenon Pharmaceuticals Inc.$29.3M1.70%0.50%Not reportedQ4 2014
BABAAlibaba Group Holding Ltd$24.7M1.43%0.01%Not reportedQ1 2021
DYNDyne Therapeutics, Inc.$21.3M1.24%0.58%NewQ2 2026
BBOTBridgeBio Oncology Therapeutics, Inc.$17.1M1.00%2.81%+2.9%Q3 2025
INSMINSMED Inc$12.9M0.75%0.06%Not reportedQ2 2020
MQMarqeta, Inc.$7.17M0.42%Not reportedNot reportedQ4 2021
LNZALanzaTech Global, Inc.$1.08M0.06%1.21%Not reportedQ1 2023
Q1 2026Reported May 15, 202622 positions
EWTXEdgewise Therapeutics, Inc.$169M13.65%4.98%Not reportedQ1 2021
BNBROOKFIELD Corp$141M11.46%Not reportedNot reportedQ3 2023
ASMLAsml Holding NV$125M10.16%0.02%-16.7%Q1 2022
MIRMMirum Pharmaceuticals, Inc.$122M9.92%2.17%+4.8%Q3 2019
MPLTMapLight Therapeutics, Inc.$74.9M6.07%8.15%Not reportedQ4 2025
CRMSalesforce, Inc.$73.4M5.95%0.04%+19.1%Q1 2022
CRNXCrinetics Pharmaceuticals, Inc.$56.3M4.56%1.47%-4.6%Q3 2018
ELVNEnliven Therapeutics, Inc.$50.2M4.07%2.10%-13.5%Q2 2025
PCVXVaxcyte, Inc.$50M4.05%0.60%-6.1%Q2 2020
PHVSPharvaris N.V.$49.4M4.01%2.68%Not reportedQ1 2021
AVBPArriVent BioPharma, Inc.$44.8M3.63%4.29%Not reportedQ1 2024
VRDNViridian Therapeutics, Inc.\DE$39.1M3.17%1.95%-16.0%Q1 2024
CLDXCelldex Therapeutics, Inc.$38.1M3.08%1.80%Not reportedQ2 2024
APGEApogee Therapeutics, Inc.$37.9M3.07%0.60%-21.1%Q2 2025
BMRNBiomarin Pharmaceutical Inc$37.3M3.02%0.34%Not reportedQ2 2022
FDMT4D Molecular Therapeutics, Inc.$34M2.75%6.98%Not reportedQ1 2023
BABAAlibaba Group Holding Ltd$32.3M2.62%0.01%Not reportedQ1 2021
XENEXenon Pharmaceuticals Inc.$28.2M2.29%0.50%Not reportedQ4 2014
BBOTBridgeBio Oncology Therapeutics, Inc.$19.6M1.59%2.73%+11.5%Q3 2025
VALNValneva SE$6.61M0.54%0.61%-54.1%Q2 2025
LNZALanzaTech Global, Inc.$2.53M0.21%1.57%Not reportedQ1 2023
MQMarqeta, Inc.$1.8M0.15%Not reportedNot reportedQ4 2021
Q4 2025Reported Feb 17, 202624 positions
BNBROOKFIELD Corp$160M12.46%Not reportedNot reportedQ3 2023
EWTXEdgewise Therapeutics, Inc.$133M10.31%5.04%Not reportedQ1 2021
ASMLAsml Holding NV$122M9.47%0.03%-21.9%Q1 2022
MIRMMirum Pharmaceuticals, Inc.$99.8M7.75%2.44%Not reportedQ3 2019
CRMSalesforce, Inc.$87.5M6.79%0.04%Not reportedQ1 2022
CRNXCrinetics Pharmaceuticals, Inc.$75.6M5.87%1.70%Not reportedQ3 2018
VRDNViridian Therapeutics, Inc.\DE$74.1M5.75%2.34%Not reportedQ1 2024
MPLTMapLight Therapeutics, Inc.$64.8M5.03%8.37%NewQ4 2025
ZBIOZenas BioPharma, Inc.$52.6M4.09%2.66%-27.5%Q3 2024
PHVSPharvaris N.V.$48.6M3.77%2.68%Not reportedQ1 2021
APGEApogee Therapeutics, Inc.$43M3.34%0.83%+14.0%Q2 2025
PCVXVaxcyte, Inc.$42.3M3.28%0.70%Not reportedQ2 2020
BMRNBiomarin Pharmaceutical Inc$39.2M3.05%0.34%Not reportedQ2 2022
AVBPArriVent BioPharma, Inc.$39.1M3.03%4.57%Not reportedQ1 2024
BABAAlibaba Group Holding Ltd$37.7M2.93%0.00%Not reportedQ1 2021
INSMINSMED Inc$34.8M2.70%0.09%Not reportedQ2 2020
CLDXCelldex Therapeutics, Inc.$32.6M2.53%1.80%Not reportedQ2 2024
FDMT4D Molecular Therapeutics, Inc.$27.4M2.13%6.34%+82.5%Q1 2023
BBOTBridgeBio Oncology Therapeutics, Inc.$24.6M1.91%2.45%Not reportedQ3 2025
ELVNEnliven Therapeutics, Inc.$22.8M1.77%2.49%+3.8%Q2 2025
VALNValneva SE$20.3M1.58%1.33%-1.7%Q2 2025
LNZALanzaTech Global, Inc.$2.18M0.17%6.82%Not reportedQ1 2023
MQMarqeta, Inc.$2.1M0.16%Not reportedNot reportedQ4 2021
IOBTQIO Biotech, Inc.$1.53M0.12%3.49%Not reportedQ4 2021
Q3 2025Reported Nov 14, 202526 positions
BNBROOKFIELD Corp$160M10.30%Not reportedNot reportedQ3 2023
ASMLAsml Holding NV$141M9.10%0.04%-12.1%Q1 2022
MIRMMirum Pharmaceuticals, Inc.$92.7M5.97%2.46%-15.7%Q3 2019
EWTXEdgewise Therapeutics, Inc.$86.8M5.59%5.06%Not reportedQ1 2021
CRMSalesforce, Inc.$78.3M5.04%0.03%Not reportedQ1 2022
MRUSMerus N.V.$70.6M4.55%0.99%Not reportedQ2 2016
CRNXCrinetics Pharmaceuticals, Inc.$67.7M4.36%1.72%+4.8%Q3 2018
VRDNViridian Therapeutics, Inc.\DE$51.4M3.31%2.89%Not reportedQ1 2024
BABAAlibaba Group Holding Ltd$46M2.96%0.00%-30.9%Q1 2021
ZBIOZenas BioPharma, Inc.$44.4M2.86%4.74%-11.1%Q3 2024
PHVSPharvaris N.V.$43.7M2.81%3.22%+1.5%Q1 2021
RXRXRecursion Pharmaceuticals, Inc.$38.7M2.49%1.61%-18.0%Q4 2024
AVBPArriVent BioPharma, Inc.$35.8M2.31%4.75%+3.7%Q1 2024
BMRNBiomarin Pharmaceutical Inc$35.7M2.30%0.34%Not reportedQ2 2022
PCVXVaxcyte, Inc.$33M2.13%0.70%Not reportedQ2 2020
CLDXCelldex Therapeutics, Inc.$31M2.00%1.81%Not reportedQ2 2024
ELVNEnliven Therapeutics, Inc.$29.2M1.88%2.41%+31.5%Q2 2025
INSMINSMED Inc$28.8M1.86%0.09%-70.6%Q2 2020
VALNValneva SE$28.6M1.84%1.44%-1.3%Q2 2025
BBOTBridgeBio Oncology Therapeutics, Inc.$22.7M1.46%2.48%NewQ3 2025
APGEApogee Therapeutics, Inc.$19.9M1.28%0.84%+11.3%Q2 2025
FDMT4D Molecular Therapeutics, Inc.$17.4M1.12%4.28%Not reportedQ1 2023
LNZALanzaTech Global, Inc.$3.88M0.25%6.82%0.0%Q1 2023
MQMarqeta, Inc.$2.33M0.15%Not reportedNot reportedQ4 2021
IOBTQIO Biotech, Inc.$912K0.06%3.61%-25.1%Q4 2021
DMRADamora Therapeutics, Inc.$322K0.02%6.52%-13.4%Q3 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.